Based on eventual development of CDK4/6 inhibitor resistance and there being no approved therapies to overcome the resistance, we established a preclinical model with palbociclib-resistant breast cancer to reveal mechanisms of CDK4/6 inhibitor resistance. Here, CDK4 is linked to breast cancer.